BONDLIDO 200 mg/1

lidocaine · SYSTEM · MEDRx USA, Inc.

No Recall HistoryCurrently in Shortage

Plain English

BONDLIDO is a system containing lidocaine at 200 mg/1, taken topical. Manufactured by MEDRx USA, Inc..

Key Facts

Brand Name: BONDLIDO
Generic Name: lidocaine
NDC Code (Product): 83708-111
Manufacturer: MEDRx USA, Inc.
Strength: 200 mg/1
Dosage Form: SYSTEM
Route: TOPICAL
Marketing Status
Application #: NDA215029
Drug Class: Amide Local Anesthetic [EPC]; Antiarrhythmic [EPC]
Marketing Start: 10/08/2025

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

drug ineffective3,508 reports

pain3,113 reports

fatigue2,954 reports

nausea2,928 reports

headache2,731 reports

off label use2,507 reports

dyspnoea2,088 reports

pneumonia1,941 reports

sinusitis1,916 reports

diarrhoea1,891 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE BONDLIDO (lidocaine topical system 10%) is indicated in adults for relief of pain associated with post-herpetic neuralgia (PHN). BONDLIDO contains lidocaine, an amide local anesthetic, and is indicated in adults for relief of pain associated with post-herpetic neuralgia (PHN) ( 1 ).

Dosage & Administration

2 DOSAGE AND ADMINISTRATION Due to differences in bioavailability, the efficacy of a lidocaine topical system does not necessarily correlate with dosage strength. Refer to the dosing instructions for the specific product being used ( 2 ). Apply BONDLIDO to intact skin to cover the most painful area. Apply the prescribed number of topical systems (maximum of two) only once for up to 12 hours in a 24-hour period (2) . Apply firm pressure for 20 seconds to ensure adequate adherence. 2.1 Important Dosage and Administration Information Due to differences in bioavailability, the efficacy of a lidocaine topical system does not necessarily correlate with dosage strength (i.e., concentration). Comparing different products on a nominal percentage-for-percentage basis may be misleading and the appropriate strength for a given indication may vary by product. Refer to the dosing instructions for the specific product being used. [see Clinical Pharmacology (12.3) ] . When BONDLIDO is used concomitantly with other products containing local anesthetic agents, the total amount of drug absorbed from all formulations must be considered. 2.2 Application Instructions Clearly instruct and advise patients…

Contraindications

4 CONTRAINDICATIONS BONDLIDO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product. BONDLIDO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product ( 4 ).

Drug Interactions

7 DRUG INTERACTIONS Antiarrhythmic Drugs: When BONDLIDO is used in patients receiving Class I antiarrhythmic drugs (such as tocainide or mexiletine), the toxic effects are additive and potentially synergistic. Consider risk/benefit during concomitant use ( 7.1 ). Local Anesthetics: When BONDLIDO is used concomitantly with other products containing local anesthetic agents, the effects are additive. The amount absorbed from all formulations must be considered for safe use ( 7.2 ). 7.1 Antiarrhythmic Drugs When BONDLIDO is used in patients receiving Class I antiarrhythmic drugs (such as tocainide or mexiletine), the toxic effects are additive and potentially synergistic. Consider risk/benefit during concomitant use. 7.2 Local Anesthetics When BONDLIDO is used concomitantly with other products containing local anesthetic agents, the effects are additive. The amount absorbed from all formulations must be considered for safe use. 7.3 Drugs That May Cause Methemoglobinemia When Used with BONDLIDO Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics…

Adverse Reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Accidental Exposure [see Warnings and Precautions (5.1) ] Excessive Dosing/Overexposure to Lidocaine [see Warnings and Precautions (5.2) ] Methemoglobinemia [see Warnings and Precautions (5.3) ] Application Site Reactions [see Warnings and Precautions (5.4) ] Hypersensitivity Reactions [see Warnings and Precautions (5.5) ] Eye Irritation [see Warnings and Precautions (5.6) ] The following adverse reactions associated with the use of lidocaine were identified in clinical trials or postmarketing reports for lidocaine. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and subcutaneous tissues : blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erosions, erythema, exfoliation, flushing, irritation, papules, petechia, pruritus, vesicles, and abnormal sensation. Immune system : angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria. …

Frequently Asked Questions

What is BONDLIDO used for?

BONDLIDO contains lidocaine. It is a system taken topical. Consult your doctor for specific uses.

Is BONDLIDO a controlled substance?

BONDLIDO is not classified as a controlled substance by the DEA.

What is the generic name for BONDLIDO?

The generic name for BONDLIDO is lidocaine. There are 12 other brand versions of lidocaine.

What is the NDC code for BONDLIDO 200 mg/1?

The NDC (National Drug Code) for BONDLIDO 200 mg/1 is 83708-111, listed by MEDRx USA, Inc..

Product NDC

83708-111

Package NDC

83708-111-01

Other Lidocaine Brands

See all →

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)